Considering the established evidence on CV benefit, GLP-1 RA and SGLT2i should be considered to be the first choice in patients with T2D at high CV risk, alone or in combination with metformin or each other [158]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.